Share-based Payment Arrangement, Expense of Calidi Biotherapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Calidi Biotherapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Calidi Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $529,000, a 23% decline year-over-year.
  • Calidi Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,285,000, a 35% decline year-over-year.
  • Calidi Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,957,000, a 39% decline from 2023.
  • Calidi Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,809,000, a 6.3% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Calidi Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,285,000 $529,000 -$162,000 -23% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $2,447,000 $522,000 -$229,000 -30% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $2,676,000 $607,000 -$281,000 -32% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $2,957,000 $627,000 -$559,000 -47% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $3,516,000 $691,000 -$418,000 -38% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $3,934,000 $751,000 -$329,000 -30% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $4,263,000 $888,000 -$546,000 -38% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $4,809,000 $1,186,000 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $1,109,000 +$47,000 +4.4% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $1,080,000 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $1,434,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $1,062,000 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3

Calidi Biotherapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,957,000 -$1,852,000 -39% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $4,809,000 +$287,000 +6.3% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $4,522,000 01 Jan 2022 31 Dec 2022 10-K 15 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.